Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC4 | P56524 | 1/20 | 0.54 |
| ▸ | HSD11B1 | P28845 | 8/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.44 |
| ▸ | FFAR2 | O15552 | 3/20 | 0.44 |
| ▸ | GSK3B | P49841 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1770012 | 0.97 | HDAC4 (0.58) | HDAC4HSD11B1ALDH1A1CHRM2CHRM1 | |
| SCHEMBL1769973 | 0.95 | HDAC4 (0.57) | HDAC4HSD11B1ALDH1A1CHRM2CHRM1 | |
| SCHEMBL1769917 | 0.93 | HSD11B1 (0.51) | HDAC4HSD11B1ALDH1A1GSK3BSMN1; SMN2 | |
| SCHEMBL1770373 | 0.84 | HDAC4 (0.56) | HDAC4HSD11B1ALDH1A1FFAR2SMN1; SMN2 | |
| SCHEMBL3443916 | 0.84 | HDAC4 (0.56) | HDAC4HSD11B1ALDH1A1FFAR2SMN1; SMN2 | |
| SCHEMBL8225678 | 0.83 | HDAC4 (0.54) | HDAC4HSD11B1ALDH1A1FFAR2SMN1; SMN2 | |
| SCHEMBL2550 | 0.83 | HDAC4 (0.54) | HDAC4HSD11B1ALDH1A1CHRM2CHRM1 | |
| SCHEMBL16507538 | 0.82 | AKR1C1 (0.58) | HDAC4HSD11B1ALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL9864404 | 0.82 | HSD11B1 (0.50) | HDAC4HSD11B1ALDH1A1CHRM2CHRM1 | |
| SCHEMBL7047849 | 0.82 | SLC6A3 (0.47) | CHRM2CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110112151-A1 | COMPOUND CAPABLE OF INHIBITING 11-BETA HYDROXYSTERIOD DEHYDROGENASE | STERIX LIMITED (GB) | 2011-05-12 | — | — | US | disclosed |
| EP-2257528-A2 | 1 IBETA-HYDROXYSTEROID DEHYDROGENASE INHIBITORS | Sterix Limited (GB) | 2010-12-08 | — | — | EP | disclosed |
| US-7816375-B2 | Ligands for monoamine receptors and transporters, and methods of use thereof | SEPRACOR INC. (US) | 2010-10-19 | — | — | US | disclosed |
| US-7816375-B2 | Ligands for monoamine receptors and transporters, and methods of use thereof | SEPRACOR INC. (US) | 2010-10-19 | — | — | US | disclosed |
| US-7816375-B2 | Ligands for monoamine receptors and transporters, and methods of use thereof | SEPRACOR INC. (US) | 2010-10-19 | — | — | US | disclosed |
| US-20100093706-A1 | MULTIMEDIATOR TRANSPORTER INHIBITORS FOR USE IN TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | PREXA PHARMACEUTICALS, INC. (US) | 2010-04-15 | — | — | US | disclosed |
| US-20100093706-A1 | MULTIMEDIATOR TRANSPORTER INHIBITORS FOR USE IN TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | PREXA PHARMACEUTICALS, INC. (US) | 2010-04-15 | — | — | US | disclosed |
| US-20100093706-A1 | MULTIMEDIATOR TRANSPORTER INHIBITORS FOR USE IN TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | PREXA PHARMACEUTICALS, INC. (US) | 2010-04-15 | — | — | US | disclosed |
| US-20090258901-A1 | LIGANDS FOR MONOAMINE RECEPTORS AND TRANSPORTERS, AND METHODS OF USE THEREOF | AQUILA BRIAN M | 2009-10-15 | — | — | US | disclosed |
| US-20090258901-A1 | LIGANDS FOR MONOAMINE RECEPTORS AND TRANSPORTERS, AND METHODS OF USE THEREOF | AQUILA BRIAN M | 2009-10-15 | — | — | US | disclosed |
| US-20030050309-A1 | Ligands for monoamine receptors and transporters, and methods of use thereof | SEPRACOR INC. | 2003-03-13 | — | — | US | disclosed |
| EP-0970090-B1 | SUBSTITUTED 4-ARYLMETHYLENE-2-IMINO-2,3-DIHYDROTHIAZOLES AND DERIVATIVES AND THEIR PHARMACEUTICAL USE | KNOLL GMBH (DE) | 2002-06-05 | — | — | EP | disclosed |
| WO-2002022572-A2 | LIGANDS FOR MONOAMINE RECEPTORS AND TRANSPORTERS, AND METHODS OF USE THEREOF (NEUROTRANSMISSION) | SEPRACOR, INC. (US) | 2002-03-21 | — | — | WO | disclosed |
| US-6187802-B1 | 3-(1-(3,4-DICHLOROPHENYL)CYCLOBUTYL)-5,6-DIHYDROIMIDAZO(2,1-B) THIAZOLE, FOR EXAMPLE; ADMINISTERING TO TREAT DEPRESSION, ANXIETY, PARKINSON'S DISEASE, OBESITY, COGNITIVE DISORDERS, SEIZURES, AND FOR NEUROPROTECTION AGAINST STROKE | KNOLL AKTIENGESELLSCHAFT (DE) | 2001-02-13 | — | — | US | disclosed |
| EP-0970090-A1 | SUBSTITUTED 4-ARYLMETHYLENE-2-IMINO-2,3-DIHYDROTHIAZOLES AND DERIVATIVES AND THEIR PHARMACEUTICAL USE | Knoll AG (DE) | 2000-01-12 | — | — | EP | disclosed |
| WO-1998041528-A1 | SUBSTITUTED 4-ARYLMETHYLENE-2-IMINO-2,3-DIHYDROTHIAZOLES AND DERIVATIVES AND THEIR PHARMACEUTICAL USE | KNOLL AKTIENGESELLSCHAFT (DE) | 1998-09-24 | — | — | WO | disclosed |
| US-5047432-A | Antidepressants | THE BOOTS COMPANY PLC (GB) | 1991-09-10 | — | — | US | disclosed |
| US-4925879-A | ANTIDEPRESSANTS | BOOTS COMPANY, PLC (GB) | 1990-05-15 | — | — | US | disclosed |
| EP-0191542-B1 | ARYLCYCLOBUTYLALKYL AMINES AND THEIR USE AS ANTIDEPRESSIVE MEDICINES | The Boots Company PLC (GB) | 1988-06-08 | — | — | EP | disclosed |
| EP-0191542-A1 | Arylcyclobutylalkyl amines and their use as antidepressive medicines | The Boots Company PLC (GB) | 1986-08-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030050309-A1 | Ligands for monoamine receptors and transporters, and methods of use thereof | SLC6A2, OPRL1, SLC18A2 | HDAC4 4506/4885HSD11B1 721/4885ALDH1A1 873/4885 |
| US-20100093706-A1 | MULTIMEDIATOR TRANSPORTER INHIBITORS FOR USE IN TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | SLC6A4, SLC18A2, SLC6A2 | HDAC4 1278/4885HSD11B1 1208/4885ALDH1A1 490/4885 |
| US-20110112151-A1 | COMPOUND CAPABLE OF INHIBITING 11-BETA HYDROXYSTERIOD DEHYDROGENASE | HSD11B1, HSD11B2, HSD3B1 | HDAC4 1338/4885HSD11B1 1/4885ALDH1A1 307/4885 |
| US-20090258901-A1 | LIGANDS FOR MONOAMINE RECEPTORS AND TRANSPORTERS, AND METHODS OF USE THEREOF | SLC6A2, OPRL1, SLC18A2 | HDAC4 4506/4885HSD11B1 721/4885ALDH1A1 873/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.